Overview of Dr. Lee
Dr. Benjamin Lee is a thoracic surgeon in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Queens, and Valley Hospital. He received his medical degree from New York Medical College and has been in practice 15 years. He is one of 12 doctors at Valley Hospital and one of 27 doctors at New York-Presbyterian Queens who specialize in Thoracic Surgery. He has more than 40 publications and over 500 citings.
Office
525 E 68th St
# M404
New York, NY 10065Fax+1 646-962-0203
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Thoracic Surgery, 2007 - 2009
- University of California Davis HealthResidency, Surgery, 2001 - 2007
- New York Medical CollegeClass of 2001
Certifications & Licensure
- CA State Medical License 2003 - Present
- NY State Medical License 2007 - 2026
- FL State Medical License 2017 - 2019
- NJ State Medical License 2009 - 2017
- American Board of Surgery Surgery
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Clinical Trials
- Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Start of enrollment: 2007 Oct 12
Publications & Presentations
PubMed
- Evaluating ChatGPT as a patient resource for frequently asked questions about lung cancer surgery-a pilot study.Dana Ferrari-Light, Robert E Merritt, Desmond D'Souza, Mark K Ferguson, Sebron Harrison
The Journal of Thoracic and Cardiovascular Surgery. 2024-09-24 - 5 citationsSub-Lobar Resection: The New Standard of Care for Early-Stage Lung Cancer.Benjamin E Lee, Nasser Altorki
Cancers. 2023-05-25 - 8 citationsSurgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial.Benjamin Lee, Nathan Mynard, Abu Nasar, Jonathan Villena-Vargas, Oliver Chow
The Journal of Thoracic and Cardiovascular Surgery. 2023-01-01
Press Mentions
- Surgical Resection After Neoadjuvant Durvalumab and Radiation Is Feasible and Safe in Non-Small Cell Lung Cancer: Results from a Randomized TrialMay 17th, 2022
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: